Acorda Pharmaceutical vector logo
Acorda's lead product, Ampyra (dalfampridine), is an FDA-approved treatment for symptomatic treatment of walking impairment in adults with MS. The company is also developing other promising therapies for MS, including injectable dalfampridine and riluzole, as well as therapies for other neurological disorders, such as amyotrophic lateral sclerosis (ALS).
